- Home
- FXNC vs CRGX Comparison
FXNC vs CRGX Comparison
Compare FXNC & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FXNC
- CRGX
- Stock Information
- Founded
- FXNC 1907
- CRGX 2021
- Country
- FXNC United States
- CRGX United States
- Employees
- FXNC N/A
- CRGX N/A
- Industry
- FXNC Major Banks
- CRGX
- Sector
- FXNC Finance
- CRGX
- Exchange
- FXNC Nasdaq
- CRGX Nasdaq
- Market Cap
- FXNC 201.9M
- CRGX 213.5M
- IPO Year
- FXNC N/A
- CRGX 2023
- Fundamental
- Price
- FXNC $19.66
- CRGX $4.12
- Analyst Decision
- FXNC Strong Buy
- CRGX Hold
- Analyst Count
- FXNC 1
- CRGX 7
- Target Price
- FXNC $21.00
- CRGX $4.67
- AVG Volume (30 Days)
- FXNC 18.1K
- CRGX 759.8K
- Earning Date
- FXNC 04-30-2025
- CRGX 05-16-2025
- Dividend Yield
- FXNC 3.18%
- CRGX N/A
- EPS Growth
- FXNC N/A
- CRGX N/A
- EPS
- FXNC 0.60
- CRGX N/A
- Revenue
- FXNC $64,346,999.00
- CRGX N/A
- Revenue This Year
- FXNC $57.36
- CRGX $58.18
- Revenue Next Year
- FXNC $4.25
- CRGX N/A
- P/E Ratio
- FXNC $32.63
- CRGX N/A
- Revenue Growth
- FXNC 31.48
- CRGX N/A
- 52 Week Low
- FXNC $14.75
- CRGX $3.00
- 52 Week High
- FXNC $26.97
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- FXNC 44.17
- CRGX 40.15
- Support Level
- FXNC $19.29
- CRGX $3.99
- Resistance Level
- FXNC $21.96
- CRGX $4.66
- Average True Range (ATR)
- FXNC 0.69
- CRGX 0.20
- MACD
- FXNC 0.12
- CRGX -0.05
- Stochastic Oscillator
- FXNC 37.84
- CRGX 17.72
About FXNC First National Corporation
First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. Loan products and services include personal loans, residential mortgages, home equity loans, and commercial loans. Deposit products and services include checking and savings. The Bank's wealth management division offers estate planning, investment management of assets, retirement accounts, and estate settlement.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.